Novo Nordisk is Receding – but the Comeback Potential is Great
Pfizer Withdraws from Oral Weight Loss Medications!
Strong Pullback, Strong Perspective!
Reading Time: 2 minutes
Novo Nordisk has recently had setbacks - disappointing study results and the growing success of Eli Lilly have called its market leadership into question. However, those who write off Novo underestimate the strategic depth of the company. CEO Lars Fruergaard Jørgensen continues to see Novo at the forefront of obesity therapies - and not without reason: the pipeline is highly specialized, the experience in metabolic medicine has been built over decades, and the expansion of production capacities, particularly in the USA, is progressing swiftly....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
